HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that a peer-reviewed article in JACC: Advances demonstrated that a risk prediction algorithm incorporating the credit card-sized HeartBeam ECG device can accurately identify heart attack risk in patients presenting with chest pain. The proof-of-concept study evaluated 184 patients and found that the algorithm achieved an “area under the curve” (“AUC”) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms, rising to 92.9% when a personal, symptom-free baseline ECG was available for comparison. The company said the results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program.
The study, published in JACC: Advances, underscores the potential of portable ECG technology to aid in the early detection of heart attacks, a critical factor in reducing mortality and improving outcomes. HeartBeam's device, which is the size of a credit card, is designed for use outside of medical facilities, enabling patients to record ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG. This platform technology has already received FDA clearance for arrhythmia assessment and 12-lead ECG synthesis software, as noted on the company's indications for use page.
The implications of this study are significant for emergency medicine and cardiac care. Chest pain is one of the most common reasons for emergency department visits, and rapid, accurate risk stratification is essential. The HeartBeam algorithm's high AUC values suggest it could effectively identify patients at low risk of heart attack, potentially reducing unnecessary hospital admissions and healthcare costs, while also flagging high-risk patients who require immediate intervention. The addition of a personal baseline ECG further enhances accuracy, highlighting the value of routine cardiac monitoring for individuals with known risk factors.
HeartBeam holds over 20 issued patents related to its technology, which is designed to deliver actionable heart intelligence wherever the patient is. The company's forward-looking statements, as detailed in its disclaimer, note that actual results may differ due to various risks and uncertainties. For the latest updates, visit the company's newsroom. The full press release is available at this link.
